Life-threatening infections following rituximab therapy in renal transplant patients with mixed cryoglobulinemia

Clinical Nephrology

Volumn 66, Issue 5, 2006, Pages 395-396

  Basse, G ^a   Ribes, D ^a   Kamar, N ^a   Esposito, L ^a   Rostaing, L ^a  

^a CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CREATININE; FLUCONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TSUKUBAENOLIDE;

ACUTE KIDNEY FAILURE; ADULT; CASE REPORT; CLINICAL PROTOCOL; CREATININE BLOOD LEVEL; CRYOGLOBULINEMIA; FASCIITIS; FEMALE; FOLLOW UP; HEPATITIS C; HERPES SIMPLEX; HOSPITALIZATION; HUMAN; HUMAN TISSUE; HYPERTENSION; INFECTION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MENINGOENCEPHALITIS; POSTOPERATIVE PERIOD; PROTEINURIA;

EID: 33750883662     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp66395     Document Type: Letter

References (4)

1. Horwitz SM, Negrin RS, Blume KG et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2004; 103: 777-783.
2. Roccatello D, Baldovino S, Rossi D et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant. 2004; 19: 3054-3061.
3. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med. 2001; 345: 1000.
4. Zaja F, De Vita S, Mazzaro C et al.: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003: 101: 3827-3834.